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A B S T R A C T 
The solubility of the drug clenbuterol in thin films of surfactant-free 
Eudragit NE30D has been measured. Light microscopy and differential 
scanning calorimetry were supplemented by a technique based on 
measurement of the rate of drug release *rom the films. The clenbuterol 
crystals had the form of a fractal, as could be shown by a computer 
simulation of diffusion-controlled aggregation. 
I N T R O D U C T I O N 
When preparing polymeric, sustained-release carriers for a drug, it is 
useful to know the solubility of the drug in the polymer. The release kinetics 
depend inter alia on whether the drug exists in the dissolved or the 
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suspended condition (1). We wished to determine the solubility of the drug 
clenbuterol in thin films of the polacrylate Eudragit NE30D. Both polarising 
light microscopy and differential scanning calorimetry (DSC) offer 
themselves as methods. With the former, the solubility is estimated by 
identifying the drug concentration at which crystals are first observed to 
form within the polymer. With DSC, the first appearance of a drug melting 
peak identifies the presence of solid drug (2), and hence the limit of 
solubility. We supplement these methods with two others, based on 
measurement of the rate of drug release from the thin films. If such a film 
contains only dissolved drug, then the release process can be described by a 
simple, diffusional model (3a). If, however, the film also contains suspended 
drug, the rate of drug release will be altered (1). We exploit this difference 
in release rate to estimate drug solublity within the film. With the first 
technique, a non-steady state model for the presence of dissolved drug is 
fitted to experimental drug release data obtained for films having a wide 
range of drug loading. The shape of the functional relationship between 
fitted diffusivity and drug loading can then be used to estimate at which drug 
loading suspended drug first appears within the films. With the second 
technique, this model is extended to account for the presence of suspended 
drug. This is readily achieved by using a numerical method, which has the 
added advantage that realistic, non-sink boundary conditions can be 
recognized. By fitting this model to experimental drug release results, a 
direct calculation of the drug solubility within the film should be possible. In 
the present paper we contrast the results obtained with these methods with 
those obtained using microscopy and DSC. Additionally, we relate some 
observations of the crystal form of clenbuterol within the polymer film. 
M A T E R I A L S A N D M E T H O D S 
Preparation of Drug-Loaded Thin Films: Frieze dried Eudragit NE30D 
(Rohm, Weiterstadt, Germany) was first refluxed for 90 h in water to 
remove its indiginous surfactant. This procedure is necessary to ensure an 
isotropic system (4). Drug-loaded films of ca. 50 /Ltm thickness were then 
prepared from this purified polymer by solvent evaporation, as described 
before (5). The basic drug clenbuterol (Boehringer Ingelheim, Ingelheim, 
Germany) was used (pKa=8.85): 
Thin films having drug loadings in the range 0-25% w/w were prepared, and 
the thickness of each determined using an Elcometer (Elcometer 
Instruments, Manchester, England). 
Estimation of Solubility from Drug Release Rate: The rate of release of 
clenbuterol from each thin film into a pH8 phosphate buffer solution was 
determined using a horizontal diffusion cell, as described before (6). Each 
result was expressed as a release profile of m a ( t ) /m 0 versus t, where m a(t) is 
the mass of drug released after time t, and m Q is the original mass of drug in 
the film at t=0. Two diffusional models were then used to estimate the 
solubility of the drug in the films. The first model is for drug release from a 
film containing only dissolved drug. The linear form of the diffusion 
equation is solved using a numerical, finite-difference technique, as 
CI 
FIGURE 1 
Model for drug release from a t h i n f i l m containing 
dissolved and suspended drug. 
described before (6). Fitting this model to the experimental release profiles 
using an improved simplex method (7) yielded the best value for drug 
diffusivity, D . This was then plotted against drug loading to estimate the 
drug solubility. The second model is an extension of the first, and is 
illustrated in Fig . l . We define the total concentration of drug within the film, 
c t o t (x,t) , to consist of the concentrations of both dissolved, c<jjss(x,t), and 
suspended, c S U Sp(x,t), drug (Fig. la). The numerical solution to the diffusion 
equation must be modified to account for the presence of suspended drug. 
Thus, at t=0, the value of ccjj s s(x,t) is equal to the solubility of the drug in 
the film, c s , and decreases with time as a result of diffusion out of the film 
(Fig. lb). After each time step of the numerical calculation, At, the value of 
cdiss( x^) i s increased spontaneously to c s at those points where suspended 
drug is still present (Fig. lc). The concentration of suspended drug 
remaining at these points is accordingly reduced, eventually falling to zero 
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FIGURE 2 
Clenbuterol d i f f u s i v i t y (D) versus drug loading 
of t h i n films of Eudragit NE30D. Arrow: estimated 
s o l u b i l i t y of drug. 
and leaving only dissolved drug present. The solution to the model yields 
both theoretical concentration-distance profiles of drug within the film, and 
theoretical drug release profiles of m a ( t ) /m 0 versus t. The latter were then 
fitted to each experimental release profile as before. In this case, however, 
the best value for drug solubility within the film is obtained directly. 
Microscopical Examination of Thin Films: The thin films were examined 
under a polarising light microscope with hot stage (Zeiss Standard), and 
photographs taken with a Nikon C35 camera (Nikon, Japan). 
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FIGURE 3a 
Simulated drug concentration p r o f i l e s within 
thin f i l m for d i f f e r e n t values of Dt/1 2 (40% w/w 
suspended drug). 
Thermal Analysis of Thin Films: The thermal behaviour of the thin films was 
examined using differential scanning calorimetry (DSC) with a Mettler 
Model TC10A (Greifensee, Switzerland). A heating/cooling rate of 10 K/min 
was used over the temperature range 280-405 K. 
R E S U L T S A N D DISCUSSION 
It is known that drug diffusivity within an isotropic film can be 
calculated by fitting the model for dissolved drug to experimental release 
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FIGURE 3b 
Simulated drug release p r o f i l e s for 
increasing amount of suspended drug 
i n t h i n f i l m . 
profiles (6). The fitted diffusivities obtained for the present system are 
dependent on the drug loading (Fig. 2), as is found for many systems (3b). 
Using the relation: D(c) = D Q e k c , the results at low drug loadings (up to 
the arrow on Fig. 2) yield the values D Q = 7.58x10*^ Cm^/s and k = 0.16 
cirr//xg. At high drug loadings (above the arrow on Fig. 2), the experimental 
coordinates deviate from this exponential relation. This effect can be 
ascribed to the formation of drug crystals within the film at high drug 
loadings. In the presence of drug crystals, the concentration of dissolved 
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FIGURE 4 
Release of clenbuterol from t h i n f i l m of 
Eudragit NE30D. Coordinates: experimental 
data. Curve: t h e o r e t i c a l s o l u t i o n of best 
f i t . 
drug within the film will be overestimated, and the fit of the model to the 
experimental data will yield an underestimated diffusivity. In this case, the 
point of departure of the experimental results from the exponential curve 
should correspond to the appearance of crystallized drug in the film. This 
occurs in Fig.2 at a value of 10.6% w/w clenbuterol, which we take to be the 
solubility of the drug in the polymer. 
The second model recognizes the influence of the presence of 
suspended drug on the release process, as can be appreciated from the 
theoretical concentration-distance profiles within a film shown in Fig. 3a. 
The discontinuity in each profile represents the moving boundary existing 
between the inner region of the film containing both dissolved and 
suspended drug and the outer region, where only dissolved drug remains. 
The profiles are curved, as a result of the non-steady state nature of the 
model, in contrast to steady state models (8). The theoretical release profiles 
in Fig. 3b illustrate how an increasing concentration of suspended drug 
within the film produces increased rates of drug release at constant 
diffusivity. This effect can be exploited to determine drug solubility within 
the film. Thus, Fig. 4 shows a typical experimental release profile 
(coordinates) together with the best fit of the model to these coordinates 
(curve). From this fit it was possible to determine not only the diffusivity but 
also the solubility. The results are compiled in the Table for two drug 
loadings. The values for D are somewhat higher than those obtained with 
the first model for only dissolved drug (cf. Fig. 2). The presence of 
suspended drug is recognized with the second model, thereby avoiding the 
aforementioned overestimation of the concentration of dissolved drug within 
the film. Of interest here is the value obtained for the solubility of 
clenbuterol, ca. 13.5% w/w. 
TABLE 
Results of fit of theoretical model to experimental release profiles. 
Drug loading n 
[%w/w] 
r l l 
w/w] 
16 
20 
4 
4 
4.18 ± 0.899 
2.68 ± 0.114 
13.5 ± 0.2 
13.8 ± 0.3 
1.20 
T [ ° C ] 
FIGURE 5 
DSC-thermograms for clenbuterol-loaded t h i n 
films of Eudragit NE30D. 
This value is higher than that obtained from the first model. It is also 
higher than that suggested from the microscopy, where it was possible to 
observe the presence of crystals at clenbuterol loadings as low as ca. 10% 
w/w. These melted at ca. 85° C, a temperature substantially lower than the 
melting point of the pure drug and indicating some interaction of the drug 
with the polymer. The corresponding DSC-thermograms (Fig. 5) first show a 
recognizable drug melting peak at a drug loading of ca. 12% w/w. The 
microscopical method is, therefore, evidently more sensitive than the DSC 
method for estimating drug solubility in such systems. The higher value 
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FIGURE 6b 
D e t a i l of ce n t r a l aggregate of drug c r y s t a l i n 
thin f i l m . Scale as above. 
40 min 
120 min 
FIGURE 7 
Simulation of c r y s t a l growth by d i f f u s i o n -
c o n t r o l l e d aggregation. 
found from the release experiments may have been caused by oversaturation 
of the films with drug. They were prepared immediately before use in an 
experiment, whereas those for the microscopical and DSC experiments were 
stored for some days before being examined. 
A careful examination of the individual drug crystals present in the 
films reveals that some are built up of two distinct crystal forms (Fig. 6a). A 
central crystal is present, which is surrounded by feathery-like projections 
spreading out into the surrounding polymer. The shape of the central 
aggregate (Fig. 6b) indicates that it is a fractal. It can indeed be obtained 
almost exactly by a simple computer simulation of diffusion-controlled 
aggregation within an isotropic medium (Fig. 7). For this simulation it was 
assumed that the molecules are initially dissolved within the film, through 
which they can freely diffuse. At single points within the oversaturated film, 
some of the drug crystallizes to form a seed. As a result of their thermal 
rnotion, the remaining dissolved drug molecules undergo a randon walk, 
which stops by crystallization on contact with the seed (9). The similarity of 
these crystal forms with the crystal shapes observed within the polymer film 
is striking. 
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